MedTrace Logo

Intravenous and Intraperitoneal Lignocaine for Perioperative Analgesia in Laparoscopic Colon Resections

NCT03105193 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-11-03

No results posted yet for this study

Summary

The aim of this study is to investigate the analgesic effects of intraperitoneal lignocaine (IPL) compared with intravenous lignocaine (IVL) after laparoscopic colon resections. We plan to run a 2 group randomized, double blind, clinical trial which will look into morphine consumption as the primary outcome.

Group 1 (IV lignocaine)- IV bolus of lignocaine and a 3 day post operative IV lignocaine infusion. Intra peritoneal (IP) bolus of normal saline + 3 day post operative IP normal saline infusion

Group 2 (IP lignocaine)- IV bolus of normal saline and a 3 day post operative IV normal saline infusion. IP bolus of lignocaine + 3 day post operative IP lignocaine infusion

Conditions

  • Laparoscopic Colon Resection
  • Perioperative Analgesia

Interventions

DRUG

IV Saline bolus and infusion

Intravenous bolus of normal saline at induction 3 day postoperative infusion of normal saline administered by ambit pump

DRUG

IP Saline bolus and infusion

Intraperitoneal bolus of normal saline down first port site. 3 day post operative intraperitoneal infusion of normal saline via an intraperitoneal line inserted by the surgeon. Infusion will be administered by ambit pump.

DRUG

IV lignocaine bolus and infusion

Intravenous lignocaine bolus at induction. 3 day postoperative IV infusion of lignocaine administered by ambit pump

DRUG

IP Lignocaine bolus and infusion

Intraperitoneal bolus of lignocaine down first port site. 3 day post operative intraperitoneal infusion of lignocaine via an intraperitoneal line inserted by the surgeon. Infusion will be administered by ambit pump.

Sponsors & Collaborators

  • University of Auckland, New Zealand

    lead OTHER

Principal Investigators

  • Andrew G Hill · The University of Auckland

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-08-17
Primary Completion
2019-12-01
Completion
2019-12-30

Countries

  • New Zealand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03105193 on ClinicalTrials.gov